BRÈVE

sur BIOSYNEX (EPA:ALBIO)

BIOSYNEX obtains its first CE markings according to the new IVDR regulations

BIOSYNEX, a group specializing in rapid tests and molecular biology, announces that it has obtained its first CE markings according to IVDR regulations. This key step strengthens the compliance of its products with European legislation and confirms the company's know-how.

The markings concern Class B and C tests to detect infectious agents, some of which are sexually transmitted, as well as a coagulation test developed by AVALUN. This facilitates future certification of other similar products.

The American subsidiary CHEMBIO DIAGNOSTICS SYSTEMS also obtained CE IVDR marking for a rapid HIV detection test. This series of accreditations underlines BIOSYNEX's ability to operate within a strict regulatory framework, constituting an important competitive advantage.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de BIOSYNEX